Adagene Inc.

Equities

ADAG

US0053291078

Biotechnology & Medical Research

Market Closed - Nasdaq 16:30:00 2024-04-18 EDT 5-day change 1st Jan Change
2.64 USD +4.35% Intraday chart for Adagene Inc. -6.38% +36.69%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Adagene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Adagene Inc. Announces Board Changes CI
Adagene Inc. Appoints Heinz-Josef Lenz to Scientific and Strategic Advisory Board CI
ADRs Close Higher, Ambow Education Holding Ltd. Climbs 117.4% DJ
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading MT
Adagene Gets China Clearance to Assess Colorectal Cancer Treatment Combination MT
Adagene Inc. Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody CI
ADRs End Higher; The9 Climbs 16% DJ
Adagene Reports Positive Data on Colorectal Cancer Treatment Combination MT
Adagene Inc. Announces Data from its Presentation at the American Society of Clinical Oncology 2024 Gastrointestinal (GI) Cancers Symposium CI
ADRs End Lower; Aslan Pharmaceuticals Declines 38% DJ
ADRs Slump, Grifols S.A. Declines 14.0% DJ
ADRs Advance; Aslan Pharmaceuticals Climbs 27% DJ
ADRs End Lower; Secoo Holding Declines 28% DJ
ADRs Close Higher; Incannex Healthcare Inc. Climbs 723.7% DJ
Adagene Inc. Presents Data Demonstrating the Best-In-Class Therapeutic Index for Masked Anti-CTLA-4 Safebody®? Adg126 CI
ADRs Close Higher, Mobilicom Ltd. Climbs 41.4% DJ
ADRs Advance, Akso Health Group Rises 29.6% DJ
Adagene Inc. Announces Resignation of Fangyong Du as Chief Technology Officer CI
Adagene Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Adagene Inc.'s Equity Buyback announced on June 29, 2022, has expired. CI
Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second Safebody® Novel Masked Antibody-Drug Conjugate CI
Tranche Update on Adagene Inc.'s Equity Buyback Plan announced on June 29, 2022. CI
Tranche Update on Adagene Inc.'s Equity Buyback Plan announced on June 29, 2022. CI
Tranche Update on Adagene Inc.'s Equity Buyback Plan announced on June 29, 2022. CI
Chart Adagene Inc.
More charts
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.64 USD
Average target price
5 USD
Spread / Average Target
+89.39%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. ADAG Stock
  4. News Adagene Inc.
  5. Adagene Gets China Clearance to Assess Colorectal Cancer Treatment Combination